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Abstract: Pomalidomide is an immunomodulatory drug for treatment of relapsed or refractory 
multiple myeloma (rrMM) in patients who often have comorbid renal conditions. To assess the 
impact of renal impairment on pomalidomide exposure, a population pharmacokinetics (PPK) 
model of pomalidomide in rrMM patients with various degrees of impaired renal function was 
developed. Intensive and sparse pomalidomide concentration data collected from two clinical 
studies in rrMM patients with normal renal function, moderately impaired renal function, 
severely impaired renal function not requiring dialysis, and with severely impaired renal func-
tion requiring dialysis were pooled over the dose range of 2 to 4 mg, to assess specifically the 
influence of the impaired renal function as a categorical variable and a continuous variable 
on pomalidomide clearance and plasma exposure. In addition, pomalidomide concentration 
data collected on dialysis days from both the withdrawal (arterial) side and from the return-
ing (venous) side of the dialyzer, from rrMM patients with severely impaired renal function 
requiring dialysis, were used to assess the extent to which dialysis contributes to the removal 
of pomalidomide from blood circulation. PPK analyses demonstrated that moderate to severe 
renal impairment not requiring dialysis has no influence on pomalidomide clearance or plasma 
exposure, as compared to those patients with normal renal function, while pomalidomide 
exposure increased approximately 35% in patients with severe renal impairment requiring 
dialysis on nondialysis days. In addition, dialysis increased total body pomalidomide clear-
ance from 5 L/h to 12 L/h, indicating that dialysis will significantly remove pomalidomide 
from the blood circulation. Thus, pomalidomide should be administered post-dialysis on the 
days of dialysis.
Keywords: hemodialysis, pomalidomide, population pharmacokinetics, renal impairment
Introduction
The IMiD® agent pomalidomide (Celgene Corporation, Summit, NJ, USA) has 
pleiotropic cytotoxic effects against multiple myeloma (MM) cells1,2 in addition to 
antiproliferative,3,4 antiangiogenic,5–7 and immunomodulatory activity.8,9 Furthermore, 
pomalidomide has potent effects on key cytokines, including IL-10, IFNγ, and TNFα.10 
Pomalidomide has been studied for treatment of various hematologic and non-neoplastic 
hematologic disorders11–13 and is approved (in combination with dexamethasone) in the 
European Union and United States for the treatment of patients with MM who have 
received ≥2 prior therapies, including lenalidomide and bortezomib (in the European 
Union; a proteasome inhibitor in the United States), and who have progressed on or 
within 60 days of completion of the last therapy or have disease progression on the 
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last therapy.14,15 This combination  (pomalidomide plus low-
dose dexamethasone) significantly increased progression-free 
survival and overall survival compared with high-dose dexa-
methasone.13 Thrombocytopenia, neutropenia, and anemia 
were the most common grade 3/4 adverse events.
Lenalidomide, pomalidomide’s IMiD analog, is metabo-
lized minimally and eliminated predominantly via urinary 
excretion in the unchanged form in humans,16 resulting in 
dosage adjustments for patients with creatinine clearance 
(CrCl) <50 mL/min.17,18 Pomalidomide is eliminated predom-
inantly through renal excretion (~73% of the administered 
dose), with <3% of the administered dose excreted in urine 
as unchanged pomalidomide across all dose levels.19 Thus, 
it is relevant to assess the influence of renal impairment on 
pomalidomide clearance and plasma exposure.
Pomalidomide population pharmacokinetics (PPK) was 
previously assessed in both healthy individuals and patients 
with relapsed or refractory MM (rrMM).20 Those analyses 
suggested that pomalidomide systemic clearance was com-
parable between the two groups. Covariate analysis showed 
pomalidomide clearance was unaffected by demographic 
factors, with the exception of sex, which had a difference 
<30%, making its clinical relevance unlikely. Furthermore, 
pomalidomide clearance was not significantly affected by 
renal function/impairment (as measured by CrCl between 
20–188 mL/min).
In a previous PPK analysis, the data set included only 
a few patients with moderately or severely impaired renal 
function. Thus, there is a need for a thorough assessment of 
the influence of impaired renal function on pomalidomide 
clearance, including more data from patients with moderately 
or severely impaired renal function.
Following the PPK analysis, two studies were conducted 
to assess the specific effect of renal function on pharmaco-
kinetics (PK), safety, and/or efficacy of pomalidomide in 
patients with renal impairment. CC-4047-MM-008 is an 
ongoing Phase 1, multicenter, open-label, dose-escalation 
study.21 The primary objective of the study was to determine 
the PK and safety of pomalidomide when given in combina-
tion with low-dose dexamethasone in patients with rrMM 
and impaired renal function. CC-4047-MM-013 is an ongo-
ing Phase 2, multicenter, open-label study to determine the 
efficacy and safety of pomalidomide in combination with 
low-dose dexamethasone in patients with rrMM and moder-
ate or severe renal impairment, including patients undergoing 
hemodialysis.22 Secondary objectives included evaluating 
the PK of pomalidomide in patients with various degrees of 
renal impairment.
The aim of this study was to use the cumulative data of 
patients with rrMM and degrees of renal impairment comor-
bidity from CC-4047MM-008 and CC-4047-MM-013 to 
evaluate the relationship of renal function measures (treated 
as both a categorical variable and a continuous variable) with 
pomalidomide clearance to assess the extent to which hemo-
dialysis contributes to the elimination of pomalidomide and 
to optimize the start time of hemodialysis after pomalidomide 
administration by simulation.
Methods
Study population and PK sampling
The PPK analysis utilized data from 63 participants in two 
clinical studies, CC-4047-MM-008 and CC-4047-MM-013. 
In the PPK data set, there is an adequate distribution of 
patients with rrMM and various degrees of impaired renal 
function (Table 1). In both studies, once-daily pomalidomide 
was administered orally. Institutional review boards or ethics 
committees (Table S1) approved both studies, and all study 
participants provided written informed consent.
Bioanalytical methodology
To determine human plasma samples for pomalidomide con-
centrations, a validated liquid chromatography–tandem mass 
Table 1 Number of patients with various degrees of impaired renal function included in the population pharmacokinetic analysis
Renal function group Classification of renal function Number of patients
CC-4047-MM-008 CC-4047-MM-013 Total
Patients with normal renal function CrCl ≥60 mL/min 8 – 8
Patients with moderately impaired renal 
function
30< eGFR <45 mL/min/1.73 m2 – 15 15
Patients with severely impaired renal 
function not requiring hemodialysis
CrCl <30 mL/min or eGFR <30 mL/
min/1.73 m2 not requiring dialysis
11 19 30
Patients with severely impaired renal 
function requiring hemodialysis
CrCl <30 mL/min or eGFR <30 mL/
min/1.73 m2 requiring dialysis
1 9 10
Total 20 43 63
Abbreviations: CrCl, creatinine clearance; eGFR, estimated glomerular filtration rate.
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spectrometry (LC-MS/MS) assay was used. The lower limit 
of quantification was 0.25 ng/mL. As an internal standard, 
plasma samples were spiked with stable labeled pomalido-
mide. These were subsequently processed by liquid-liquid 
extraction and then analyzed using reversed-phase high- 
performance liquid chromatography (HPLC) with electro-
spray MS/MS detection. HPLC was used to separate peaks.
Population PK model building
A nonlinear mixed-effect modeling program (NONMEM 
version 7.2; Icon Development Solutions, Ellicott City, MD, 
USA) was used for pomalidomide concentration-time PK 
analysis. Graphic processing was performed using S-Plus 
(version 8.2; TIBCO Software Inc, Somerville, MA, USA) 
and R-based model-building aid Perl-Speaks-NONMEM 
(PsN, version 3.5.3; Kajsa Harling and Andrew Hooker, 
Uppsala University, Uppsala, Sweden) post-processing soft-
ware. Structural model comparisons were based on goodness-
of-fit criteria and objective function value. 
Selection of the most appropriate model was based on 
prior knowledge of pomalidomide disposition, graphical anal-
ysis, and statistical evaluation. Pomalidomide concentration-
time data, per visual inspection and data-fitting criteria, were 
best described by a one-compartment structure PK model. 
This model featured the first-order absorption rate constant 
(Ka), absorption lag time, apparent central compartment 
volume of distribution, and apparent clearance (CL/F).
The inter-individual variability (IIV) in PK parameters 
assumed a log-normal distribution and was modeled as 
follows:
 P
i
 = P · ehi  (Equation 1)
with P
i
 as the parameter value for the ith individual, P as the 
typical parameter value in the population, and h
i
 as a random 
inter-individual parameter effect for the ith participant with 
a mean = 0 and variance ω2 (ie, η~N[0, w2]).
IIV or residual variability was modeled as follows:
 ln(C
ij
) = ln(C
mij
) + e
ij
  (Equation 2)
with C
ij
 and C
mij
 as the observed and model-predicted jth 
concentration in the ith participant, respectively, and e
ij
 as 
the random residual effect for the jth concentration in the ith 
participant with a mean = 0 and variance of σ2.
Visual predictive check (VPC) was used for model evalua-
tion. This compared model predictions with observations and 
provided an evaluation of model assumption and population 
parameter estimates. The final PPK model’s ability to describe 
observed concentration data was tested using simulations; 
VPCs were performed using 1000 data sets using the same 
dosages, dosing schedules, and sampling times as in the 
original data set.
The nonparametric bootstrap approach was used to evalu-
ate the stability of the final PK parameter estimates and 90% 
CI. There were 500 bootstrap data sets, and the final model 
was fit to each. Every model parameter was estimated for 
each set; 96% of the bootstrap runs were successful. For 
each of the 500 estimates, median and nonparametric 90% 
CI (5th-95th percentiles) were calculated for each parameter.
Covariate analysis
Renal function was the key covariate for the covariate analy-
sis. Both the Cockcroft-Gault equation23 and the Modification 
of Diet in Renal Disease (MDRD) equation24,25 have been 
used to calculate CrCl and eGFR:
CrCl = [(140 - age) × body weight]/(72 × serum creatinine 
level) × (0.85 for females) (Equation 3)
CrCl is capped at a physiological level of 150 mL/min.
eGFR (mL/min/1.73 m2) = 175 × (Scr,std) – 1.154 × (age) 
- 0.203 × (0.724 if female) × (1.212 if African American)  
 (Equation 4)
with Scr,std as serum creatinine level measured with a stan-
dardized assay.
The influence of renal function (treated as both a cat-
egorical variable and a continuous variable) on pomalidomide 
clearance was specifically assessed in the covariate analysis. 
Other typical covariates in the PPK data set included, but 
were not limited to, age, weight, body surface area, sex, and 
hepatic function markers.
The pomalidomide covariate model was developed using 
the stepwise covariate model-building tool of PsN. The 
stepwise covariate model has a fixed set of PK parameter–
covariate relations defined within it; predefined shapes for 
the pomalidomide continuous covariate model development 
parameter-covariate relations included either linear or power 
equations.
In the pomalidomide covariate model development, cat-
egorical covariates were included as follows:
 P = q · (1 + q
cov
· Z
ind,k
)  (Equation 5)
with q
cov
 representing the coefficient for the covariate effect 
and Z
ind,k
 as an indicator variable representing one binary 
covariate form.
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Monte Carlo simulation
Based on the developed PPK models in which renal function 
was treated as both a categorical variable and a continuous 
variable, Monte Carlo simulations were performed using 
NONMEM 7.2 to investigate whether impaired renal func-
tion would alter the plasma pomalidomide exposures. The 
plasma concentration profiles for patients with rrMM with 
various degrees of impaired renal function were simulated 
at steady state, and then the drug exposures were calculated 
by non-compartmental analysis for comparison.
Assessing effect of hemodialysis on 
pomalidomide PK
Hemodialysis may affect pomalidomide PK to an extent that 
necessitates dosage adjustment. The need for dosage adjust-
ment arises when a significant fraction of pomalidomide is 
removed by hemodialysis. In such cases, a change in the 
dosage regimen, such as a supplemental dose following 
hemodialysis, may be appropriate.
The hemodialysis clearance (CL
D
) was estimated from 
the plasma concentration-time data collected on hemodialy-
sis days from both the withdrawal (“arterial”) and return-
ing (“venous”) sides of the dialyzer in patients requiring 
hemodialysis:
 CL
D
 = Q * (C
a
–C
v
)/C
a
  (Equation 6)
with C
a
 as concentration in plasma entering the dialyzer 
(arterial line), C
v
 as concentration in plasma exiting the dia-
lyzer (venous line), and Q as the flow rate of blood through 
the dialyzer.
CL
D
 was compared with pomalidomide plasma clear-
ance to assess the effect of hemodialysis on pomalidomide 
PK. Simulations were conducted to identify dosages and 
the starting time of hemodialysis after pomalidomide 
administration that achieved the goal for patients requiring 
hemodialysis.
Results
Analysis populations and demographics
Sixty-three participants with various degrees of impaired 
renal function were included in the final PPK analysis data set 
(Table 1). Baseline characteristics are summarized in Table 2. 
The participants had a median age of 69 (range, 46–86) years. 
The median CrCl and the median eGFR were 28.3 (range, 
8.7–115.4) mL/min and 27 (range, 5–84) mL/min/1.73 m2, 
respectively.
Assessment of the relationship of 
measures of renal function (treated 
as categorical variable) and the 
pomalidomide clearance
Visual examination of the dose-normalized average concen-
tration vs time profiles by renal function group ( Figure 1) 
showed similar pomalidomide concentrations among patients 
Table 2 Demographic characteristics of analysis population
Variable Study Value, median 
(min, max)
Age (years) CC-4047-MM-013 71 (55, 86)
CC-4047-MM-008 67 (46, 84)
Total 69 (46, 86)
ALT (U/L) CC-4047-MM-013 15 (8, 58)
CC-4047-MM-008 21 (6, 47)
Total 17 (6, 58)
ALB (g/L) CC-4047-MM-013 36.4 (0, 45.6)
CC-4047-MM-008 37.5 (30, 42)
Total 37 (0, 45.6)
ALP (U/L) CC-4047-MM-013 78 (38, 1154)
CC-4047-MM-008 70.5 (39, 177)
Total 76 (38, 1154)
AST (U/L) CC-4047-MM-013 21 (10, 68)
CC-4047-MM-008 26.5 (13, 43)
Total 22 (10, 68)
Bilirubin (µmol/L) CC-4047-MM-013 6.8 (3, 18)
CC-4047-MM-008 6.8 (5.1, 12)
Total 6.8 (3, 18)
Body mass index CC-4047-MM-013 26.6 (19.6, 38)
CC-4047-MM-008 28.3 (19.6, 36.9)
Total 26.8 (19.6, 38)
Body weight (kg) CC-4047-MM-013 74.4 (41.2, 110)
CC-4047-MM-008 83.9 (39.9, 116.6)
Total 78.2 (39.9, 116.6)
CrCl (mL/min) CC-4047-MM-013 26.1 (8.7, 73.7)
CC-4047-MM-008 32.3 (12.3, 115.4)
Total 28.3 (8.7, 115.4)
eGFR (mL/min/ 
1.73 m2)
CC-4047-MM-013 25.8 (5, 45.1)
CC-4047-MM-008 29 (5, 84)
Total 27 (5, 84)
Height (cm) CC-4047-MM-013 168 (132, 194)
CC-4047-MM-008 169.1 (136.9, 189.8)
Total 168 (132, 194)
LDH (U/L) CC-4047-MM-013 227 (115, 1684)
CC-4047-MM-008 391.5 (88, 1954)
Total 262 (88, 1954)
Total protein (g/L) CC-4047-MM-013 63 (0.1, 113)
CC-4047-MM-008 73.5 (52, 107)
Total 68 (0.1, 113)
Abbreviations: ALB, albumin; ALT, alanine aminotransferase; ALP, alkaline 
phosphatase; AST, aspartate aminotransferase; CrCL, creatinine clearance; eGFR, 
estimated glomerular filtration rate; LDH, lactate dehydrogenase.
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with rrMM with normal renal function (CrCl ≥60 mL/
min), with moderate renal impairment (30< eGFR ≤45 mL/
min/1.73 m2), with severe renal impairment not requir-
ing hemodialysis (CrCl <30 mL/min or eGFR <30 mL/
min/1.73 m2), and with severe renal impairment requiring 
hemodialysis.
Pomalidomide concentration-time profiles were ade-
quately described by a one-compartment model with first-
order absorption. Renal function was incorporated as a 
categorical variable to assess the relationship of renal function 
measures and pomalidomide clearance. None of the other 
tested covariates were significant enough to be included in 
the final model using the stepwise covariate model based on 
the predefined statistical criteria for inclusion of a covariate.
The PPK parameters from the final PPK model are 
presented in Table 3. The model parameters were precisely 
estimated with the base model as observed from the narrow 
90% bootstrap CI. The estimated IIV and associated covari-
ance were reasonably precise.
The bootstrap replicates showed similar median values 
of the parameters with narrow 90% CIs, compared with the 
original NONMEM estimates (Table 3). These results suggest 
that the final model is stable and robust.
As shown in Figure 2, VPC evaluation demonstrated 
that the 90% prediction intervals of the median, 5th, and 
95th percentiles of simulated results could cover the 
observed data percentiles appropriately, and no obvious 
bias was noted. Overall, the observed pomalidomide 
Figure 1 Average dose-normalized pomalidomide concentration vs time profiles by renal function group.
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Table 3 Pharmacokinetic parameter estimates from the final model with renal function treated as a categorical variable
PK parameter Estimate Bootstrap median estimate 90% bootstrap CIa
Ka (1/h) 0.724 0.774 0.533–1.23
V/F (L) 58.300 58.521 51.597–66.055
CL/Fnormal (L/h) 5.130 5.159 4.283–6.069
CL/F ratio (group 2 vs group 1) 1.020 1.019 0.848–1.195
CL/F ratio (group 3 vs group 1) 1.010 1.018 0.871–1.169
CL/F ratio (group 4 vs group 1) 0.724 0.729 0.606–0.844
Tlag (h) 0.154 0.183 0.002–0.43
ω2 (Ka) 0.782 0.804 0.441–1.387
ω2 (V/F) 0.139 0.136 0.069–0.236
ω (V/F):ω (CL/F) 0.163 0.156 0.088–0.236
ω2 (CL/F) 0.198 0.189 0.121–0.273
δ2 0.341 0.321 0.194–0.459
Notes: CL/Fnormal, apparent clearance for patients with normal renal function; Ka, absorption rate constant; Tlag, lag time; V/F, apparent volume of distribution; ω
2, variance of 
interpatient variability; δ2, variance of intra-patient variability. Group 1 represents patients with normal renal function; group 2 represents patients with moderately impaired 
renal function; group 3 represents patients with severely impaired renal function not requiring hemodialysis; and group 4 represents patients with severely impaired renal 
function requiring hemodialysis. aBootstrap CI values were taken from bootstrap calculation.
Abbreviation: PK, pharmacokinetics.
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concentration variability was adequately described by the 
estimated IIV.
Taken together, the final PPK model adequately character-
ized pomalidomide concentrations in the log range of −1.3666 
to 5.196 (ie, 0.255–180.569 ng/mL). This enabled the use of 
the model to predict pomalidomide exposure for Monte Carlo 
simulations, making the final PPK model appropriate.
Developing dosage recommendation 
for patients with rrMM with different 
levels of renal function by Monte Carlo 
simulation
Per regulatory agencies’ guidance, specific dosing recom-
mendations should be constructed based on the study results 
using the aforementioned model for the relationships between 
renal function and relevant PK parameters. Simulations 
are encouraged as a means to identify dosages and dosing 
intervals for patients with different levels of renal function.
Monte Carlo simulations were conducted based on the 
final PPK model in which renal function was treated as a 
four-level categorical variable. Fifty patients with various 
degrees of renal impairment (normal renal function, mod-
erately impaired renal function, severely impaired renal 
function not requiring hemodialysis, and severely impaired 
renal function requiring hemodialysis) were included in each 
virtual trial. Two hundred virtual trials were performed using 
Monte Carlo simulations.
The mean values of the plasma concentration profiles 
at steady state obtained from 200 Monte Carlo simulations 
were not remarkably different among patients with various 
degrees of renal impairment (Figure 3). The mean values of 
the plasma exposures (area under the plasma concentration-
time curve) obtained from the simulations were not remark-
ably different among patients with normal renal function, 
moderately impaired renal function, and severely impaired 
renal function not requiring hemodialysis. Patients with 
severely impaired renal function requiring hemodialysis 
Figure 2 Visual predictive checks for time profiles of pomalidomide concentrations by group. 
Notes: Group 1: patients with normal renal function; Group 2: patients with moderately impaired renal function; Group 3: patients with severely impaired renal function 
not requiring hemodialysis; Group 4: patients with severely impaired renal function requiring hemodialysis. Circles represent observed data. Lines represent the 50th (solid) 
percentiles of the observed data. Shaded areas represent nonparametric 95% CI about the 50th (pink) percentiles for the corresponding model-predicted percentiles.
Abbeviations: LCONC, logarithm-transformed concentration; NTIME, nominal time.
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showed 35.8% higher exposure compared with patients with 
normal renal function (Table 4).
Assessment of the relationship of renal 
function measures of CrCl or eGFR and 
pomalidomide clearance
Historically, the Cockcroft-Gault equation for calculating 
CrCl has been widely used to define the degree of renal 
impairment, and it is used commonly in the application of 
drug dosing guidance for patients with renal impairment. In 
the CC-4047-MM-008 study, CrCl was used to define the 
degree of renal impairment. Recently, the MDRD eGFR 
equation has increasingly been used as the standard in clinical 
practice to assess renal function. In the CC-4047-MM-013 
study, eGFR was used to define the degree of renal impair-
ment. Therefore, it is critical to assess the relationship 
between renal function treated as a continuous variable (CrCl 
or eGFR) and pomalidomide clearance.
As shown in Figure 4, pomalidomide clearance increased 
with increasing CrCl or eGFR and becomes constant when 
the CrCl is larger than approximately 40 mL/min or when the 
eGFR is larger than approximately 25 mL/min/1.73 m2. The 
reverse-hockey-stick equation was selected to characterize 
the relationship between pomalidomide clearance and CrCl 
or eGFR:
CL/F  = intercept + slope × CrCl or eGFR (when CrCl or 
eGFR ≤ CrCl
0
 or eGFR
0
)
  = constant (when CrCl or eGFR > CrCl
0
 or eGFR
0
)  
 (Equation 7)
Based on goodness-of-fit and statistical criteria, a one-
compartment model with Ka and a reverse-hockey-stick 
relationship between CL/F and CrCl or eGFR adequately 
described pomalidomide PK (data not shown) and was chosen 
for the final structural PPK model (Table 5). 
Assessment of the extent to which 
hemodialysis contributes to the 
elimination of pomalidomide
Because pomalidomide is loosely bound to plasma proteins 
(12%–44%), the effect of hemodialysis on pomalidomide 
PK was assessed in patients with end-stage renal disease 
undergoing hemodialysis on both hemodialysis and nondi-
alysis days to determine the extent to which hemodialysis 
contributed to the elimination of pomalidomide in both the 
CC-4047-MM-008 and CC 4047-MM-013 studies. CL
D
 was 
calculated and the median value from seven patients was 
approximately 12 L/h, which is higher than pomalidomide 
total body clearance (5 L/h), indicating that the hemodialysis 
procedure removed pomalidomide from circulation. There-
fore, it is critical to optimize the starting time of hemodialysis 
relative to pomalidomide administration. Simulations based 
on the final PPK model and observed CL
D
 were conducted 
under two different scenarios.
• Scenario 1: hemodialysis begins after pomalidomide 
administration.
• Scenario 2: hemodialysis is completed before pomalido-
mide administration.
Figure 3 Median values of the plasma concentration profiles with 90% CI from 200 
Monte Carlo simulations based on the final population pharmacokinetic model with 
renal function treated as a categorical variable.
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Table 4 Summary of systemic pomalidomide exposure (AUC) for patients with various degrees of renal impairment from 200 Monte 
Carlo simulations based on the final population pharmacokinetic model with renal function treated as a categorical variable
Group Classification of renal function Mean of AUC
(ng/mL•h)
90% CI of AUC
(ng/mL•h)
Mean of normalized
AUC (%)
90% CI of normalized
AUC (%)
Group 1 60< CrCl <120 mL/min 787.8 601.9–1025.9 100.0 76.4–130.2
Group 2 30< CrCl <60 mL/min 773.5 609.8–949.9 98.2 77.4–120.6
Group 3 15< CrCl <30 mL/min 789.7 628.3–1000.7 100.2 79.7–127.0
Group 4 0< CrCl <15 mL/min 1070.0 846.9–1339.5 135.8 107.5–170.0
Notes: Group 1 represents patients with normal renal function; group 2 represents patients with moderately impaired renal function; group 3 represents patients with 
severely impaired renal function not requiring hemodialysis; and group 4 represents patients with severely impaired renal function requiring hemodialysis.
Abbreviations: AUC, area under the plasma concentration-time curve from 0 to 24 h; CrCl, creatinine clearance.
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The simulated concentration vs time profiles under 4 h 
hemodialysis for these two scenarios are presented in Figure 5 
and Figure 6, respectively. In scenario 1, pomalidomide expo-
sures on hemodialysis days were significantly lower than on 
nondialysis days under different starting times of hemodialy-
sis. Quantitative assessment suggested that the pomalidomide 
exposures for scenario 1 were approximately 50%–70% of 
those on nondialysis days and were likely to result in insuf-
ficient pomalidomide exposures on hemodialysis days. On 
the other hand, in scenario 2, pomalidomide exposure was 
approximately 83%–91% of that on nondialysis days and 
provided adequate pomalidomide exposures for patients 
with severely impaired renal function requiring hemodi-
alysis. When a 6 h hemodialysis procedure simulation was 
conducted, similar results were obtained (data not shown).
Discussion
A quantitative PPK analysis of pomalidomide PPK in both 
healthy individuals and patients with rrMM has been previ-
ously reported.20 That study, which investigated the associated 
IIV and residual variability and assessed the effect of covari-
ates of interest, reported that both groups showed comparable 
plasma exposures. However, patients with rrMM showed 
longer duration of terminal-phase plasma concentrations, 
indicating a deeper pomalidomide tissue/organ distribution. 
Previously, it was shown within the graphic analysis that, 
although renal function (determined by CrCl) appeared to 
have a positive correlation with CL/F, the predefined sta-
tistical significance level was not reached in the univariate 
covariate analysis. In patients with normal, mild, and mod-
erate renal impairment, the geometric mean CL/F appeared 
Table 5 Pharmacokinetic parameter estimates from the final model with renal function treated as a continuous variable
PK parameter CrCl as renal function marker eGFR as renal function marker
Estimate 95% bootstrap CIa Estimate 90% bootstrap CIa
Ka (1/h) 0.68 0.522–0.931 0.678 0.526–0.948
V/F (L) 60.7 54.393–68.717 60.5 54.502–69.225
Intercept (L/h) 3.71 2.321–4.796 3.96 2.577–5.086
Slope 0.0469 0.013–0.095 0.0483 0.001–0.115
CrCl0 (mL/min) or eGFR0 (mL/min/1.73 m
2) 37.7 35.027–50.343 26.0 25.01–30.899
ω2 (Ka) 0.986 0.638–1.467 0.99 0.64–1.46
ω2 (V/F) 0.0293 0–0.081 0.0278 0–0.082
ω2 (intercept) 0.163 0.076–0.383 0.147 0.062–0.297
ω2 (slope) 0.3 0–0.813 0.516 0–3.837
δ2 0.351 0.217–0.471 0.351 0.221–0.492
Notes: Ka, absorption rate constant; V/F, apparent volume of distribution; ω2, variance of inter-patient variability; δ2, variance of intra-patient variability. aBootstrap CI values 
were taken from bootstrap calculation.
Abbreviations: CrCl, creatinine clearance; eGFR, estimated glomerular filtration rate; PK, pharmacokinetics.
Figure 4 Relationship between pomalidomide apparent clearance (CL/F) and CrCl (A) or eGFR (B). 
Note: Red lines represent the locally weighted scatterplot smoothing line.
Abbreviations: CrCl, creatinine clearance; eGFR, estimated glomerular filtration rate.
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comparable, and it was concluded that renal impairment 
did not significantly affect pomalidomide clearance over 
the CrCl range of 20 to 188 mL/min. This previous PPK 
analysis data set only included a limited number of patients 
with moderately or severely impaired renal function. Thus, 
there was a need for a thorough assessment of the influence 
of the impaired renal function on pomalidomide clearance, 
especially in patients with severely impaired renal function.
With an additional 63 patients with various degrees of renal 
impairment (eight patients with normal renal function, 15 with 
moderately impaired renal function, 30 with severely impaired 
renal function not requiring hemodialysis, and ten with severely 
impaired renal function requiring hemodialysis) from two 
clinical studies (CC-4047-MM-008 and CC-4047-MM-013), 
the effect of renal impairment on pomalidomide total body 
clearance and plasma exposure was critically re-examined in 
the current PPK analysis. Consistent with previous findings 
that renal function as measured by CrCl of 20 to 188 mL/min 
did not remarkably affect pomalidomide clearance or plasma 
exposure, moderate or severe renal impairment did not affect 
pomalidomide clearance or plasma exposure. When renal 
function was regarded as a four-level categorical variable 
(group 1: normal renal function; group 2: moderately impaired 
renal function; group 3: severely impaired renal function not 
requiring hemodialysis; and group 4: severely impaired renal 
function requiring hemodialysis), the analysis demonstrated 
that patients with moderately impaired renal function and 
patients with severely impaired renal function not requiring 
hemodialysis showed similar plasma clearance compared with 
patients with normal renal function (CL/F ratios of 1.02 [90% 
CI, 0.848–1.195] and 1.01 [90% CI, 0.871–1.169], respec-
tively) (Table 3). Patients with severely impaired renal func-
tion requiring hemodialysis had approximately 30% slower 
clearance compared with patients with normal renal function 
(CL/F ratio of 0.724 [90% CI, 0.606–0.844]). None of the other 
tested covariates were significant enough to be included in the 
final model using the stepwise covariate model based on the 
predefined statistical criteria for inclusion of a covariate. Monte 
Carlo simulation results based on the final PPK model with 
renal function treated as a categorical variable demonstrated 
comparable pomalidomide exposures among the four groups 
of patients, further confirming that the difference in clearance 
was not small (Table 4).
Figure 5 Simulated plasma concentration vs time profiles under different starting times of the hemodialysis procedure after pomalidomide administration.
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Figure 6 Simulated plasma concentration vs time profiles when the hemodialysis 
procedure is completed before pomalidomide administration. 
Notes: Red line represents the mean of the simulated concentration vs time profile. 
Light blue shaded area represents the 90% CI of the simulated concentration vs 
time profile. Blue arrows represent pomalidomide dosing time. Bold green lines 
represent hemodialysis procedure (lasting for 4 h).
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When renal function was treated as a continuous vari-
able (CrCl or eGFR), the analysis demonstrated that the 
intercept of the total pomalidomide clearance (CL/F) vs 
renal function marker (3.71 and 3.96 L/h for CrCl and eGFR, 
respectively) curve was approximately 70% of pomalidomide 
total clearance (5.13 L/h), suggesting that non-renal clear-
ance contributed roughly 70% of the total body clearance 
of pomalidomide, significantly more than renal clearance. 
In addition, the slope of the CL/F vs renal function marker 
(CrCl or eGFR) curve was shallow, consistent with the finding 
that pomalidomide was eliminated via non-renal clearance, 
and its total body clearance was not sensitive to changes in 
renal function (Table 5). Further, Monte Carlo simulation 
based on the final PPK model with renal function treated as a 
continuous variable showed consistent results with the Monte 
Carlo simulation based on the final PPK model with renal 
function treated as a categorical variable: the mean values of 
the plasma exposures (area under the plasma concentration-
time curve) were not remarkably different among the four 
groups of patients (group 1: patients with CrCl of ≥60 mL/
min; group 2: patients with 30< eGFR ≤45 mL/min/1.73 m2; 
group 3: patients with CrCl of <30 mL/min or eGFR of <30 
mL/min/1.73 m2; group 4: patients with CrCl of <15 mL/
min or eGFR of <15 mL/min/1.73 m2). Patients from group 
4 showed mildly higher exposure (39.5% and 27% for CrCl 
and eGFR, respectively) compared with patients from group 
1 (normal renal function group).
Analyses from hemodialysis data showed that the median 
values of the CL
D
 were 2-fold higher than pomalidomide 
total body clearance (12 and 5 L/h, respectively), indicating 
that the hemodialysis procedure removed pomalidomide 
from the blood. A simulation was conducted to optimize 
the start time of hemodialysis after pomalidomide admin-
istration. When the hemodialysis procedure began after 
pomalidomide administration, pomalidomide exposure on 
hemodialysis days was approximately 50%–70% of that 
on nondialysis days and was likely to result in insufficient 
pomalidomide exposures on hemodialysis days. However, 
when the hemodialysis procedure was completed before 
pomalidomide administration on hemodialysis days, 
pomalidomide exposure was approximately 83%–91% of 
that on nondialysis days and provided adequate pomalido-
mide exposures for patients with severely impaired renal 
function requiring hemodialysis.
In conclusion, this PPK analysis showed that there is no 
remarkable difference in pomalidomide exposures among 
different renal function groups, and there was a 35% higher 
exposure in patients with severe renal impairment requiring 
hemodialysis on nondialysis days. In addition, pomalidomide 
is cleared predominately via non-renal routes, accounting for 
approximately 70% of pomalidomide total body clearance. 
Thus, pomalidomide total body clearance is not sensitive to 
changes in renal function, as demonstrated by the relatively 
large intercept value (non-renal clearance) and shallow slope 
value in the relationship between pomalidomide CL/F and 
renal function markers (CrCl or eGFR). For patients with 
rrMM with end-stage renal disease requiring hemodialysis, 
the hemodialysis procedure removed pomalidomide from 
the blood; thus, pomalidomide should be administered after 
hemodialysis procedures.
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Supplementary material
Table S1 List of IECs/IRBs for CC-4047-MM-008 and CC-4047-MM-013 studies
Study Site number Name/address of IEC/IRB
CC-4047-MM-008 001 The University of Texas MD Anderson Cancer Center IRB, 1400 Pressler, Unit 1437, Houston, TX 
77030-4009, USA
The University of Texas MD Anderson Cancer Center Surveillance Committee FWA-363, 1515 
Holcombe Blvd, Unit 198, Houston, TX 77030-4009, USA
002 HCA-HealthONE Institutional Review Board, 
4900 S. Monaco Street, 230 Denver, CO 80237, USA
003 Western Institutional Review Board, 1019 39th Ave SE, Suite 120, Puyallup, WA 98374, USA
Western Institutional Review Board, 3535 Seventh Avenue, SW Olympia, WA 98502-5010, USA
004 Institutional Review Board of the Cleveland Clinic Foundation, 9500 Euclid Avenue OS-I, Cleveland, 
OH 44195, USA
006 Emory University Institutional Review Board, 1599 Clifton Rd NE, 5th floor, Atlanta, GA 30322, USA
100 Local REB: 
Nova Scotia Health Authority Research Ethics Board, Centre for Clinical Research, 5790 University 
Avenue, Room 118 Halifax, Nova Scotia, Canada B3H 1V7
CC-4047-MM-013 101 Comite de Protection des personnes OUEST III, CHU de la Miletrie, Pavilion Rene Le Blaye, Porte 9, 2 
Rue de la Miletrie, BP 577, 86021 Poitiers Cedex, France
103 Comite de Protection des personnes OUEST III, CHU de la Miletrie, Pavilion Rene Le Blaye, Porte 9, 2 
Rue de la Miletrie, BP 577, 86021 Poitiers Cedex, France
202 Ethics Committee of the Medical Faculty of Eberhard Karis University and the University Hospital 
Tuebingen, Gartenstrasse 47, 72074 Tuebingen, Germany
301 CEC: 
Direction of Pharmaceutical Studies and Research, 284 Mesogeion str, Cholargos, 115 62 Athens, 
11528, Greece 
LEC: 
Ethics Committee of General Hospital of Athens “Alexandra”, 80 Vas Sofias Ave and 1 Lourou str, 
Athens, 11528, Greece
401 Comitato Etico Regionale delle Marche, Via Conca, n 71, 60126 Ancona, Italy
Formally known as: 
Comitato Etico AOU Ospedali Riuniti
402 Comitato Etico Provinciale di Reggio Emilia, Dipartmento Insfrastruttura Ricerca e Statistica, Azienda 
Ospedaliera Arcispedale Santa Maria Nuova/ IRCCS, Viale Umberto I, 50, 42123 Reggio Emilia, Italy
403 COMITATO ETICO BRIANZA, Via Pergolesi, 33 – 20090 Monza (MB), Italy
Previous EC: 
Comitato Etico Interaziendale per le Province de Lecco Como e Sondrio, AO della Provincia di Lecco, 
Via dell’Eremo 9/11, 23900 Lecco, Italy
404 Comitato Etico Milano Area 2, Segreteria Tecnico Scientifica ed Amministrativa, Fondazione IRCCS Ca’ 
Granda Ospedale Maggiore Policlinico, Palazzo Uffici, Via F. Sforza n. 28, 20122 Milano, Italy
501 Stichting Beoordeling Ethiek Biomedisch Onderzoek (Stichting BEBO), Stationsstraat 9, 9401 KV Assen, 
the Netherlands
502 Stichting Beoordeling Ethiek Biomedisch Onderzoek (Stichting BEBO), Stationsstraat 9, 9401 KV Assen, 
the Netherlands
601 CEIC Área de Salud de Salamanca, Hospital Clínico Universitario - 2ª planta Antiguo Edificio de 
Maternidad, Paseo de San Vicente, 58-182 
37007 Salamanca, Spain
603 CEIC de l’Hospital Universitari Doctor Peset, Genoveva Pallarés Sancho-TelloC/ San Lázaro s/n. Edifici 
de Riscos Laborals 1r Pis. 46017 València, Spain
701 North West Centre of Research Ethics Committees, Barlow House, 3rd Floor, 4 Minshull Street, 
Manchester, M1 3DZ, England
702 North West Centre of Research Ethics Committees, Barlow House, 3rd Floor, 4 Minshull Street, 
Manchester, M1 3DZ, England
703 North West Centre of Research Ethics Committees, Barlow House, 3rd Floor, 4 Minshull Street, 
Manchester, M1 3DZ, England
(Continued)
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Study Site number Name/address of IEC/IRB
705 North West Centre of Research Ethics Committees, Barlow House, 3rd Floor, 4 Minshull Street, 
Manchester, M1 3DZ, England
801 Ethics Committee of the City of Vienna, Thomas-Klestil-Platz 8/2, 1030 Vienna, Austria
802 Ethics Committee of the Medical University of Vienna, Borschkegasse 8b / E06, 1090 Vienna, Austria
803 Kepler University Hospital, Ethics Committee of the Province of Upper Austria, Neuromed Campus, 
Wagner-Jauregg-Weg 15, A-4020 Linz, Austria
Abbreviations: CEC, central ethics committee; CEIC, Comité Ético de Investigación Clínica [clinical research ethics committee]; EC, ethics committee; FWA, Federalwide 
Assurance; IEC, institutional ethics committee; IRB, institutional review board; LEC, local ethics committee; REB, research ethics board.
Table S1 (Continued)
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